rs17697419 — VEGFC

Diabetic retinopathy and its most vision-threatening complication, diabetic macular edema¹¹ diabetic macular edema
Diabetic macular edema (DME) is the leading cause of vision loss in working-age adults with diabetes; fluid accumulates in the central retina (macula) when the inner blood-retinal barrier breaks down, causing distortion and central vision loss, arise from a combination of chronic hyperglycemia, neuroinflammation, and pathological retinal neovascularization. The VEGFC gene²² VEGFC gene
Vascular Endothelial Growth Factor C — the primary driver of lymphangiogenesis, signaling through VEGFR3 (FLT4), but also active in vascular endothelial cell proliferation and angiogenesis through VEGFR2 at chromosome 4q34 encodes a growth factor that in the retinal context appears to modulate pathological vessel permeability and neovascularization through the DLL4-NOTCH1 signaling pathway. The rs17697419 variant falls in an intron of VEGFC, and its minor A allele is associated with significantly reduced risk of diabetic retinopathy — a rare example of a protective VEGFC variant in diabetic eye disease.

rs17697419 is an intronic variant at position 176,687,012 on chromosome 4 (GRCh38). It does not alter the VEGF-C protein sequence directly. Its intronic location in a region that regulates VEGFC transcript processing suggests it may influence VEGFC expression level or mRNA isoform ratios — mechanisms consistent with the known regulatory architecture of intronic variants near splice regulatory elements.

Under hyperglycemic conditions, VEGF-A upregulates VEGF-C expression in retinal pigment epithelial cells, and VEGF-C in turn can break down the outer blood-retinal barrier³³ outer blood-retinal barrier
The blood-retinal barrier consists of an inner layer (tight junctions of retinal vascular endothelium) and an outer layer (tight junctions of retinal pigment epithelium); breakdown of either contributes to the fluid accumulation that defines DME through an autocrine pathway that increases vascular permeability. In hypoxic retinal endothelial cells, VEGFC drives pathological angiogenesis through phosphorylation of p38MAPK and CREB, which upregulates DLL4 and NOTCH1 — tip cell formation signals that drive new vessel sprouting. Variants that reduce VEGFC expression or functional signaling through this pathway would be expected to attenuate these pathological processes, providing a mechanistic explanation for the protective effect of the A allele.

The primary evidence comes from a cross-sectional candidate gene study⁴⁴ cross-sectional candidate gene study
n=2,899 white patients with T1DM or T2DM from Australian and UK ophthalmology and endocrine clinics; 980 with no DR, 1,919 with any DR; 13 VEGFC tag SNPs genotyped; logistic regression adjusted for clinical covariates by Kaidonis et al. (Ophthalmology, 2015). Three VEGFC SNPs — rs17697419, rs17697515, and rs2333526 — survived multiple testing correction:

• rs17697419: OR 0.67 (95% CI 0.52–0.85), p = 0.001
• rs17697515: OR 0.62 (95% CI 0.47–0.81), p = 0.001; also specifically associated with DME in T2DM patients (OR 0.53, p = 0.004)
• rs2333526: OR 0.69 (95% CI 0.54–0.90), p = 0.005

Haplotype analysis across the 13 tag SNPs identified two independently protective haplotypes against DR development. Because rs17697419 and rs17697515 are both significant individual SNPs and likely tag the same underlying protective haplotype, the genetic signal from this region of VEGFC is consistent and replicated within the study's haplotype structure.

The evidence level is moderate: the Kaidonis study is well-powered (n=2,899, adequate for modest OR detection at MAF ~10%) and survived multiple testing correction in a candidate gene framework, but the specific SNPs have not been replicated in an independent GWAS, and functional characterization of the intronic variant's mechanism remains incomplete.

For the large majority of people (84% GG), the absence of the protective A allele is the common state — they carry the average population risk for diabetic retinopathy and should manage all modifiable risk factors (HbA1c, blood pressure, lipids) with particular attention. For A allele carriers, this genetic information is potentially reassuring but does not eliminate diabetic retinopathy risk: the OR of 0.67 reduces risk by about a third, not to zero, and the absolute benefit depends on the underlying diabetes duration and severity.

Critically, the proven evidence-based strategy for reducing DR risk — tight glycemic control — remains the most effective intervention regardless of genotype. This variant informs the biological margin, not the strategy. Carriers of the A allele who also have VEGFC rs7664413 T allele (lymphedema risk SNP in the same gene) would have partially opposing VEGFC signals depending on context (lymphatic vs. retinal vascular), highlighting the tissue-specificity of VEGFC's effects.

rs17697419 lies in the same gene and genomic region as rs7664413, the VEGFC variant associated with lymphedema risk. These two variants likely tag different regulatory elements within VEGFC and may operate independently on lymphatic versus retinal vascular phenotypes. Their haplotype relationship has not been specifically characterized.

The nearby rs17697515 shows the strongest DME-specific protective effect (OR 0.53 in T2DM DME) and is in likely linkage disequilibrium with rs17697419 based on their co-occurrence in the same haplotype analysis. rs2333526 is the third significant SNP in the same VEGFC region. The combined haplotype effect may be stronger than any single SNP in isolation.